6971:TSEKyocera Corporation Analysis
Data as of 2026-03-10 - not real-time
¥2,625.50
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Kyocera’s price is trading above its short‑term support and comfortably under the 52‑week high, with the 20‑day SMA sitting above the 50‑day SMA, suggesting a bullish technical backdrop. The RSI hovers around the neutral zone and the MACD has turned bearish, indicating mixed short‑term momentum. Fundamentally, revenue is growing at a healthy pace but profitability is modest, with ROE under 4% and operating margins in the low single digits.
The stock carries an extremely high price‑to‑earnings multiple far above the industry average, while the DCF‑derived fair value sits well below the current market price, flagging significant overvaluation. Dividend sustainability is questionable given a payout ratio well over 100%, and a debt‑to‑equity ratio above ten points to a leveraged balance sheet. Volatility is elevated, though beta remains low, and market sentiment is in an “Extreme Greed” phase, adding to the cautionary tone.
The stock carries an extremely high price‑to‑earnings multiple far above the industry average, while the DCF‑derived fair value sits well below the current market price, flagging significant overvaluation. Dividend sustainability is questionable given a payout ratio well over 100%, and a debt‑to‑equity ratio above ten points to a leveraged balance sheet. Volatility is elevated, though beta remains low, and market sentiment is in an “Extreme Greed” phase, adding to the cautionary tone.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish trend with price above support
- Bearish MACD divergence
- High valuation relative to earnings
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Revenue growth offset by thin margins
- Elevated volatility and overvaluation
- Unsustainable dividend payout
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Persistent overvaluation versus DCF fair value
- High leverage and low return on equity
- Dividend yield unlikely to be maintained
Key Metrics & Analysis
Financial Health
Revenue Growth7.50%
Profit Margin5.07%
P/E Ratio84.7
ROE3.19%
ROA1.16%
Debt/Equity10.17
P/B Ratio1.1
Op. Cash Flow¥212.7B
Free Cash Flow¥2.3B
Industry P/E29.4
Technical Analysis
TrendBullish
RSI53.0
Support¥2,468.00
Resistance¥2,817.50
MA 20¥2,665.03
MA 50¥2,446.99
MA 200¥2,049.64
MACDBearish
VolumeStable
Fear & Greed Index76.91
Valuation
Fair Value¥116.80
Target Price¥2,271.07
Upside/Downside-13.50%
GradeOvervalued
TypeGrowth
Dividend Yield1.90%
Risk Assessment
Beta0.53
Volatility44.85%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.